By Karen Roman
Aktis Oncology said it raised $175 million in Series B financing, led by RA Capital Management, with RTW Investments and Janus Henderson Investors as co-leads.
The capital will contribute to the company’s radiopharmaceuticals pipeline including AKY-1189, its first-in-class Nectin-4-targeted miniprotein radioconjugate, it stated.
“The overwhelming support from high caliber investors underscores the progress we have made on our pipeline, platform, and supply chain capabilities, exemplified by the significant opportunity for AKY-1189,” said Matthew Roden, Aktis’s President and CEO. “With over $300 million in cash, we are well-positioned to prosecute several opportunities to expand the benefit of this exciting modality into new patient populations.”
Contact:
